InvestorsHub Logo
Followers 14
Posts 734
Boards Moderated 0
Alias Born 12/09/2013

Re: willyw post# 2448

Wednesday, 04/05/2023 9:26:46 AM

Wednesday, April 05, 2023 9:26:46 AM

Post# of 3058
Hmmmmmm.
Some potential validation?


6) The FDA is currently exploring long covid treatments as a potential label for antivirals.



Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Poster Presentations:
Date: Monday, April 17, 2023
Time: 12:00 – 1:30 p.m. Central European Summer Time (CEST)
Session Title: 12e. Drug development and treatment modalities (including in vitro, animal, clinical trials, resistance)
Poster Number: P2633
Title: “EDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID”
Presenter: Yang Li, Ph.D.
---------------------
It's probably pointless to comment but I am assuming that being accepted to present at (ECCMID) offers some validity to the presentations.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News